CSIMarket
 
Cullinan Therapeutics Inc   (NASDAQ: CGEM)
Other Ticker:  
 
 
Price: $8.1400 $0.00 0.000%
Day's High: $8.2 Week Perf: -1.33 %
Day's Low: $ 7.89 30 Day Perf: -1.93 %
Volume (M): 251 52 Wk High: $ 30.19
Volume (M$): $ 2,040 52 Wk Avg: $15.17
Open: $8.05 52 Wk Low: $6.85



 Market Capitalization (Millions $) 490
 Shares Outstanding (Millions) 60
 Employees 111
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -168
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Cullinan Therapeutics Inc

Consolidated Gems, Inc., formerly Electrum International, Inc. is a Delaware corporation that was originally incorporated in Florida as We Sell for U Corp. (“We Sell for U”) on November 12, 2007. The principal stockholder of Consolidated Gems is Power Developments Pty Ltd., an Australian corporation (“Power”), an entity majority owned by the Company’s president, which owned 82.85% of Consolidated Gems as of December 31, 2016.

In December 2008, Power acquired a 96% interest in Consolidated Gems from Edward T. Farmer and certain other stockholders. Mr. Farmer resigned as Sole Director and Officer of Electrum, Joseph Gutnick was appointed President, Chief Executive Officer and a Director and Peter Lee was appointed Chief Financial Officer and Secretary. Commencing in fiscal 2009, the Company decided to focus its business on energy opportunities.

On January 29, 2009, the Company’s Board of Directors declared a 6-for-1 stock split in the form of a stock dividend that was payable in February 2009 to stockholders of record as of February 14, 2009. The Company has accounted for this bonus issue as a stock split and accordingly, all share and per share data has been retroactively restated. An aggregate of 72,000,000 shares of common stock were issued in connection with this dividend.

On March 31, 2009, the Company’s Board of Directors declared a 2-for-1 stock split in the form of a stock dividend that was payable in August 2009 to stockholders of record as of August 12, 2009. The Company has accounted for this bonus issue as a stock split and accordingly, all share and per share data has been retroactively restated. An aggregate of 86,400,000 shares of common stock were issued in connection with this dividend.

Effective on August 12, 2009, the Company completed the reincorporation from a Florida corporation to a Delaware corporation through a merger with and into its wholly-owned subsidiary, Consolidated Gems. Each issued and outstanding share of common stock, par value US$0.0001 per share, of We Sell For U Corp., a Florida-incorporated company, was automatically converted into one issued and outstanding share of common stock, par value US$0.0001 per share, of Consolidated Gems, a Delaware-incorporated company. The number of authorized shares of capital stock was increased to five hundred twenty million (520,000,000) shares, of which five hundred million (500,000,000) shares shall be Common Stock and twenty million (20,000,000) shares shall be Preferred Stock, each with a par value of US$0.0001 per share. For purposes of the Company’s reporting status with the Securities and Exchange Commission, Consolidated Gems is deemed a successor to We Sell for U.



   Company Address: One Main Street Cambridge 2142
   Company Phone Number: 410-4650   Stock Exchange / Ticker: NASDAQ CGEM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        2.62% 
BIIB        2.02% 
EXEL        2.02% 
GILD   -1.11%    
HALO   -1.11%    
NVAX   -1.11%    
• View Complete Report
   



Clinical Study

Pioneering Lupus Treatment Cullinan Therapeutics Achieves Groundbreaking FDA Clearance for CLN-978,

Published Wed, Oct 16 2024 11:00 AM UTC

Trailblazing in Autoimmune Therapies: Cullinan Therapeutics Garners FDA IND Clearance for CLN-978 in Lupus Treatment In a significant stride for autoimmune disease treatment, Cullinan Therapeutics Inc. recently received FDA clearance for its Investigational New Drug (IND) application to administer CLN-978 subcutaneously in patients with moderate to severe systemic lupus eryt...

Clinical Study

Cullinan Therapeutics Launches Innovative Global Phase 1 Clinical Trial for Systemic Lupus Erythematosus,

Published Tue, Sep 17 2024 11:00 AM UTC

Cullinan Therapeutics Embarks on Groundbreaking Global Phase 1 Clinical Trial for Systemic Lupus ErythematosusIn a significant leap forward for autoimmune disease research, Cullinan Therapeutics, a division of Cullinan Oncology Inc. (NASDAQ: CGEM), has received approval to initiate its first global Phase 1 clinical trial of CLN-978. This investigational therapy is aimed at ...

Clinical Study

Cullinan Therapeutics Submits IND for New Lupus Treatment Amidst Underperforming Shares,

Published Mon, Sep 16 2024 11:01 AM UTC

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus In a noteworthy move for both the company and patients suffering from systemic lupus erythematosus (SLE), Cullinan Therapeutics has officially submitted an Investigational New Drug (IND) application to the U...

Clinical Study

Zipalertinib A New Hope for Non-Small Cell Lung Cancer Patients with Challenging EGFR Exon 20 Insertions

Published Sat, Sep 14 2024 8:15 AM UTC

for CSIMarket.com Abstract: The emergence of targeted therapies has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), especially for patients harboring specific mutations in the epidermal growth factor receptor (EGFR). A pivotal Phase 2b study of Zipalertinib, presented at ESMO 2024 by Cullinan Therapeutics, revealed promising updated data ...

Clinical Study

Promising Horizons in NSCLC Treatment: Cullinan Therapeutics? Zipalertinib Shows Comp...

Published Sat, Jun 1 2024 11:00 AM UTC

Pioneering Progress: Cullinan Therapeutics Announces Promising Results from the Phase 2b REZILIENT1 Study of Zipalertinib in NSCLC with EGFR Exon 20 Insertion Mutations In the ever-evolving landscape of oncology research, achieving meaningful outcomes for patients with non-small cell lung cancer (NSCLC) remains an imperative. Cullinan Therapeutics has recently made signific...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com